The main pathogenetic mechanisms of skin aging (disruption of microcirculation, metabolic shifts towards atrophy with slowed renewal of the dermal intercellular substance and collagen synthesis, skin deformation) are effectively corrected using cell biorevitalization with autologous SFs.

SFs are the primary cellular component of the skin, ensuring its homeostasis and morphofunctional organization.

They perform a range of complex functions: they control the composition and structure of the extracellular matrix of the dermis (collagen, elastin, proteoglycans, and structural glycoproteins), ensuring its remodeling and renewal, as well as maintaining the physiological state of all skin layers.

Local intradermal transplantation of cultured SFs, due to their paracrine and direct replacement effects, allows replenishing the population of these cells lost during physiological involution with young and functionally active fibroblasts, which begin to synthesize the extracellular matrix, cytokines, and chemokines, mobilize immune cells, and contribute physical forces to revitalize all skin layers.

In the cell technology of hair loss treatment, including androgenic alopecia, BMCP containing the main cell populations of the hair follicle is used: dermal papilla MSCs and epithelial stem cells (ESCs) of the bulge area and interfollicular epithelium.

Their proliferation and differentiation ensure the formation of all types of hair follicle cells.

Indications for CT in aesthetic medicine include scar conditions and skin fibrosis, senile skin atrophy, and androgenic alopecia.

Treatment Scheme

The biomaterial for the production of BMCP based on autologous SFs is the patient’s skin biopsy.

Skin explantation is performed on an outpatient basis under local anesthesia, usually in the postauricular area using a DERMO PUNCH 4 mm, and does not require sutures.

For the isolation of ESCs and dermal papilla MSCs, micrograft explantation with several hair follicles is performed.

The production of a therapeutic course dose of BMCP typically requires 25-30 days.

The cell therapy course involves intradermal administration of therapeutic doses of BMCP on an outpatient basis.

For the treatment of atrophic scars, a dose of at least 2 x 10⁵ FCs per 1 cm² of scar area is used for a single transplantation. Administrations are repeated three times at intervals of 2-3 weeks.

In the case of correcting age-related skin changes, the optimal CT scheme is determined by the individual characteristics of the patient’s skin based on 5 x 10⁵ FCs per 1 cm² of the area of interest (face, neck, hands, etc.). 2-3 procedures may also be required at intervals of 2-3 weeks.

CT for alopecia also involves subcutaneous administration of BMCP in a single dose of at least 50 thousand hair follicle cells per 1 cm² of skin.

The treatment course may include 2-3 cell transplantations and can be combined with hair autotransplantation.

Effectiveness

CT of atrophic and age-related skin changes using BMCP based on SFs triggers natural processes of dermal microstructure remodeling.

After transplantation, cultured SFs fully integrate into the dermis, maintaining their biosynthetic activity for a long time.

As a result of increased synthesis of endogenous collagen and restoration of microcirculation, modifications in dermal architecture are observed, increasing collagen fiber content, enhancing skin hydration, and increasing skin density and thickness.

The skin regains a healthy color, becomes velvety, and dryness and peeling disappear.

In treating atrophic scars, the target outcome is flattening the scar and leveling its surface.

Objective assessment of effectiveness with quantitative skin relief analysis is conducted using profilometry methods, such as the Antera 3D photometric system (MIRAVEX Ltd.), and the POSAS facial wrinkle assessment scale.

The biosynthetic activity of transplanted fibroblasts increases over 12 months, providing a reparative effect lasting 3 to 5 years.

In treating alopecia, dermal papilla MSC transplantation combined with ESCs creates physiological prerequisites for hair follicle reconstruction.

Safety and Complications

During the first day after CT, edema, infiltration and tenderness, hyperemia, and itching at the injection site are possible, directly related to the invasive method; these symptoms disappear within 1-5 days.

Culturing SFs in the IBCE laboratory following international GMP standards guarantees BMCP biological safety.

Fibroblasts, as mature skin cells, have no carcinogenic risk, which has been repeatedly proven, for example, by Isolagen Technologies Inc. (USA) in observations of 1250 patients (4800 injections) over 7 years.